Sehwan Han

HER2 status in pure ductal carcinoma <i>in situ</i> and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence <i>in situ</i> hybridization and immunohistochemistry

K Park, Sehwan Han, H J Kim et al. · Histopathology · 2006 · 120 citations

Topoisomerase II-α (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy

K Park, J Kim, Sangbin Lim et al. · European Journal of Cancer · 2003 · 113 citations

Topoisomerase Ii-α, Breast Oncology, Oncology +9

Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial

Hyun‐Ah Kim, Jong Won Lee, Seok Jin Nam et al. · Journal of Clinical Oncology · 2019 · 88 citations · Full text

E2F1 Expression is Related with the Poor Survival of Lymph Node-positive Breast Cancer Patients Treated with Fluorouracil, Doxorubicin and Cyclophosphamide

Sehwan Han, Kyeongmee Park, Byung‐Noe Bae et al. · Breast Cancer Research and Treatment · 2003 · 80 citations

Breast Oncology, E2f1 Expression, Medicine +7

Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR)

Jisun Kim, Woosung Lim, Eun‐Kyu Kim et al. · BMC Cancer · 2014 · 66 citations · Full text